Advertisement
UK markets close in 3 hours 52 minutes
  • FTSE 100

    8,169.95
    +27.80 (+0.34%)
     
  • FTSE 250

    20,289.78
    +130.06 (+0.65%)
     
  • AIM

    777.65
    +2.72 (+0.35%)
     
  • GBP/EUR

    1.1832
    -0.0002 (-0.02%)
     
  • GBP/USD

    1.2679
    -0.0025 (-0.20%)
     
  • Bitcoin GBP

    51,385.16
    -495.07 (-0.95%)
     
  • CMC Crypto 200

    1,355.34
    -34.06 (-2.45%)
     
  • S&P 500

    5,473.23
    +41.63 (+0.77%)
     
  • DOW

    38,778.10
    +188.94 (+0.49%)
     
  • CRUDE OIL

    80.36
    +0.03 (+0.04%)
     
  • GOLD FUTURES

    2,325.00
    -4.00 (-0.17%)
     
  • NIKKEI 225

    38,482.11
    +379.67 (+1.00%)
     
  • HANG SENG

    17,915.55
    -20.57 (-0.11%)
     
  • DAX

    18,109.44
    +41.23 (+0.23%)
     
  • CAC 40

    7,602.41
    +30.84 (+0.41%)
     

LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

ORLANDO, Fla., May 23, 2024--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 1:40 p.m. CT in Austin, TX.

The live and archived webcast can be accessed through the Investors section of the Company's website at https://ir.lensar.com. The webcast will be available for one month after the presentation has been posted.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522972770/en/

Contacts

Thomas R. Staab, II, CFO
ir.contact@lensar.com

Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com